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The recent benefit–risk framework (BRF) developed by the Food and Drug Adminis-
tration (FDA) is intended to improve the clarity and consistency in communicating
the reasoning behind the FDA's decisions, acting as an important advancement in US
drug regulation. In the PDUFA VI implementation plan, the FDA states that it will
continue to explore more structured or quantitative decision analysis approaches;
however, it restricts their use within the current BRF that is purely qualitative. By
contrast, European regulators and researchers have been long exploring the use of
quantitative decision analysis approaches for evaluating drug benefit–risk balance. In
this paper, we show how quantitative modelling, backed by decision theory, could
complement and extend the FDA's BRF to better support the appraisal of evidence
and improve decision outcomes. After providing relevant scientific definitions for
benefit–risk assessment and describing the FDA and European Medicines Agency
(EMA) frameworks, we explain the components of and differences between qualita-
tive and quantitative approaches. We present lessons learned from the EMA experi-
ence with the use of quantitative modelling and we provide evidence of its benefits,
illustrated by a real case study that helped to resolve differences of judgements
among EMA regulators.
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1 | BACKGROUND
Drug regulators decide whether a new medical product can be
granted marketing authorization by assessing the drug's benefit–risk
balance, that is, “balancing the desired effects or ‘benefits’ of a medi-
cine against its undesired effects or ‘risks’”.1 This is often a challenging
and complex task given the extensive body of evidence submitted by
the applicant of a New Drug Application (NDA) or Biologics Licensing
Application (BLA). A number of additional considerations going
beyond the typical measures of a drug's benefits and risks can further
complicate the evaluation procedure, including the severity of the
condition, the unmet clinical need based on the availability of current
therapies, the uncertainty about how available clinical trial data might
translate to broader use after approval, and the potential need for risk
management tools.2,3
Explicit value judgements on prescription drugs' effects and their
trade-offs are necessary to understand their benefit–risk balance.
Although clinical trials provide scientifically objective data about
safety, efficacy and quality, regulators make subjective judgements
about what evidence concerns the intended human use of the drug,
how to evaluate the safety and efficacy data, how clinically relevant
the evidence is, how relatively important they are, and other
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considerations. In short, the benefit–risk balance of a drug depends
on both objective clinical data and its subjective interpretation.
The FDA's benefit–risk framework (BRF) is an important
advancement in the drug regulatory landscape.3 Following its earliest
conception,4 the FDA has been legally committed to its phased
implementation for use within the regulatory review process and
documentation of NDAs and BLAs in accordance with the Prescrip-
tion Drug User Fee Act (PDUFA) V in 2012 and PDUFA VI in
2017.3 The goal of the FDA's BRF is to “improve the clarity and
consistency in communicating the reasoning behind drug regulatory
decisions”, helping drug sponsors to better understand the factors
that contribute to decisions but also ensuring that FDA assessments
are readily understood.5
Although in the PDUFA VI implementation plan the FDA states
that it will continue to explore “more structured or quantitative deci-
sion analysis approaches, methods, and tools”, it also restricts their
use within the current, purely qualitative framework, not leaving
room for a possible extension to a fully quantitative method.3 By
contrast, European regulators and researchers have been exploring a
role for quantifying the benefit–risk balance as part of the approval
processes, through “explicit” decision-making approaches involving
well-defined evaluation criteria, their relative importance, and data
relating to product performance.6,7 Overall, in contrast to quantita-
tive decision analysis, qualitative approaches do not allow for the
quantification of values, uncertainties and trade-offs, nor their aggre-
gation. Based on cognitive psychology, behavioural economics and
decision science literature, the limited capacity of the human brain
to aggregate multiple pieces of information can be obviated by
assigning that task to quantitative models so computers can combine
the information.8 Numbers can be combined in ways that are impos-
sible with words.
Such a quantitative approach could allow the FDA's BRF to sup-
port the appraisal of evidence, decision outcomes, and value commu-
nication that are vital to physician and patient decision-making. It
could also facilitate regulatory decision-making and communication in
complex decision contexts where many favourable and unfavourable
effects of unequal relative clinical importance make it difficult to agree
about the overall benefit–safety balance, or in cases surrounded by
disagreement over evidence interpretation; for example, when surro-
gate measures are used as the basis of clinical benefit in place of
actual clinical outcomes,9 including for the case of advanced therapy
medicinal products (ATMPs).10 A real example of how a quantitative
decision analysis approach facilitated a regulatory decision context
characterized by multiple favourable and unfavourable effects under
consideration is described in the relevant case study section below,
for belimumab's (Benlysta) EMA review of systemic lupus
erythematosus (SLE). An example of a problematic decision context
that could be facilitated by quantitative modelling would be
eteplirsen's (Exondys 51) FDA review, characterized by strong dis-
agreement on evidence interpretation between FDA experts and
staff.11 Finally, a recent ATMP case associated with uncertainty in
clinical benefit due to the use of surrogate endpoint would be
voretigene neparvovec (Luxturna) for which current evidence failed to
support a curative benefit for most patients, with large heterogeneity
in response rate and possible shorter duration of benefits than expected.12
Furthermore, a number of ongoing FDA activities represent addi-
tional opportunities for quantitative decision analysis methods to be
used for evidence interpretation and aggregation, further strengthen-
ing the basis for their use. Such an approach could allow the explora-
tion of patients' priorities and preferences on decisions, including
helping to address controversies about the integration of subjective
patient experience in the review process,13 as envisioned by US legis-
lators in the 21st Century Cures Act.5 Another initiative as part of
PDUFA VI would be the Model-Informed Drug Development (MIDD)
Pilot Program, involving a variety of quantitative methods for
balancing the risks and benefits of drugs in development to improve
clinical studies' efficiency and regulatory success, the output of which
could be leveraged.14 Finally, following the Cures Act, real-world evi-
dence (RWE) plays an increasing role in health care decisions, includ-
ing for monitoring of post market safety for regulatory decisions and
supporting innovative clinical trials designs, which could also be used
to inform gaps in data.15
In this paper, we show how quantitative modelling, together with
decision science, could complement and extend the FDA's qualitative
BRF and improve decision-making by the EMA's Committee for
Medicinal Products for Human Use (CHMP). In doing so, we are using
evidence from the literature to highlight the limitations of qualitative
approaches while referring to the EMA experience on quantitative
decision analysis to showcase its advantages.
2 | SCIENTIFIC DEFINITIONS AND DRUG
REGULATORY FRAMEWORKS FOR BENEFIT–
RISK ASSESSMENT
Past interviews with over 50 drug experts in six European regulatory
agencies revealed substantial differences of opinion about the mean-
ing of benefits and risks.16 Apart from incompatible meanings, many
respondents failed to distinguish between the magnitude of an effect
and the uncertainty of experiencing the effect. That confusion led the
European Medicines Agency (EMA) to adopt in 2009 the 2 × 2 matrix
shown in Figure 1.
These definitions are elaborated by EMA regulators, who use
them in describing the benefit–risk balance of a new prescription
drug.17 Briefly, any patient benefit from taking a drug is a favourable
effect, which includes the reduction or elimination of an undesirable
symptom. Any side effects attributable to the drug taken are
unfavourable effects. Uncertainty attends both kinds of effects. All
four cells contribute to the benefit–risk balance. No matter how a
drug's effects and uncertainty are measured, as they must be in mak-
ing regulatory decisions to approve or clinical decisions to prescribe,
judgements are required to interpret the evidence for its clinical rele-
vance. Performance measures of a drug and its comparator might
show a statistically significant difference, but that difference could be
clinically weak or unimportant. Thus, both objective measures and the
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subjective judgements of clinical value associated with the evidence,
when considered alongside uncertainty about the effects, define the
benefit–risk balance. Current practice is embodied in the FDA's BRF
and the EMA's 80-Day Guidance documents.18 The FDA's BRF is “a
structured, qualitative approach focused on identifying and clearly
communicating key issues, evidence and uncertainties in FDA's
benefit–risk assessment and how those considerations inform regula-
tory decisions”.3 It is composed of two key elements: first, the
Benefit–Risk Dimensions portion, outlining the critical elements that
are considered in the BRF (analysis of condition, current treatment
options, benefit, risk, and risk management), along with statements of
“evidence and uncertainties” and “conclusion and reasons”, and sec-
ond, the Benefit–Risk Integrated Assessment, combining all dimen-
sions in an overall analysis and providing an explanation or rationale
of the regulatory recommendation/decision.
By contrast, since 2015 the EMA requests the assembly of an
extended Effects Table (ET) for initial applications of new active sub-
stances and important extensions of indication applications, essen-
tially a matrix of the drug's performance across those effects that are
relevant for the purpose of licensing.17 The purpose of the ET is
to “improve consistency, transparency, and communication of the
benefit–risk assessment”; it does so by summarizing only those
favourable and unfavourable effects measured in the clinical trials for
the drug alternative(s) and comparator(s) that were taken into account
by the regulator, along with descriptions of their uncertainties. This
provides the factual basis for discussions and value judgements by the
regulators of the clinical relevance of the data and their interpretation,
leading to the judgement of the overall benefit–risk balance.18 More
precisely, the ET contains the following information: names and defi-
nitions of each effect that is relevant to the overall assessment, the
unit of measurement for each effect, data summarizing for all effects
the key outcomes of the testing intervention and comparators, a
statement of the strength of evidence and any major uncertainties or
limitation for each effect, with references identifying the relevant part
of the text or specific sources of data.
Using a common glossary for these terms along with the ET
improves decision-making transparency and value communication.
3 | QUALITATIVE, SEMI-QUANTITATIVE
AND FULLY QUANTITATIVE BENEFIT–RISK
ASSESSMENT
For decision contexts in which a drug's benefit–risk balance is
straightforward, the FDA's current qualitative BRF likely serves the
needs of assessors. However, for more complex decisions that involve
greater uncertainty about the benefit–risk balance, quantitative
approaches using decision analysis can provide useful complementary
information. A relevant past example of a quantitative benefit–risk
approach is the risk analysis conducted by the FDA's Center for Bio-
logics Evaluation and Research (CBER) for the review of a home-use
HIV test kit, which applied probability distributions and sensitivity
analyses to model uncertainty of outcomes.19 Another example is the
decision analysis conducted by the FDA's Center for Devices and
Radiological Health (CDRH) for weighing the benefits and risks of
retrievable filters in patients without pulmonary embolism.20
Four fundamental components are shared for any benefit–risk
assessment: the definition of Objectives and Criteria, the identifica-
tion of Alternatives and Options, the collection of Data and Evidence,
and the elicitation of Consequences and Preferences. Taking into
account only these components reflects a purely qualitative approach.
The approach becomes semi-quantitative if utilities or values, uncer-
tainty, and trade-offs are quantified. Combining all these components
using an aggregation model as an algorithm defines a fully quantitative
approach.7 These elements are illustrated in Figure 2.
For simpler cases, presenting only one or two favourable effects
and whose adverse effects are minor, qualitative approaches may be
sufficient. With more effects, but less than 6–10, a semi-quantitative
approach, accompanied by an ET will ensure that all effects are con-
sidered. For more effects, and when there is disagreement among
the assessors, particularly where trade-offs are involved, sensitivity
F IGURE 2 Qualitative, semi-quantitative and fully quantitative
decision analysis approaches to benefit–risk assessment. Framework
1: Four outer ovals = qualitative approach. Framework 2: + three top
rectangles = semi-quantitative approach. Framework 3: + single
bottom diamond = fully-quantitative approach
F IGURE 1 The EMA matrix
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analyses in a fully quantitative model can often provide agreement
about the decision without requiring consensus about the details. As
for the resources required for a fully-quantitative multi-criteria model,
EMA feasibility studies on five drugs that were being considered for
approval by the CHMP in 2010–2011, were conducted with the
participation of four to six experts (including the rapporteur or
co-rapporteur) within a period of six hours21 (more information on
these initiatives is provided below).
Some might wonder whether the fully quantitative approach
using an algorithm is necessary, or whether the aggregation step could
be left to the decision-makers. Evidence to answer these questions
can be found in the cognitive psychology literature. As famously
pointed out by psychologist George Miller over half a century ago, the
human brain can keep in mind at one time about five to nine pieces of
information.22 Two years earlier, Paul Meehl showed that simple, lin-
ear, additive models consistently outperformed clinical predictions of
patient behaviour.23 Although originally based on a sample of 20 stud-
ies, by 1996 an analysis of 136 comparative studies came to the same
conclusion, with only a small proportion of the studies (around 5%)
favouring clinical prediction, the underlying problem identified as the
limited human “integration” of multiple pieces of evidence. More
recent scholars in behavioural economics like Thaler and Sunstein
questioned the rationality of human judgements,24 together with Kah-
neman who acknowledged that the human brain lacks such an “inte-
grator” or that the human integrator has limited capacity.25 Limited
mental capacity causes an assessor to focus on a single or small num-
ber of effects, which Montibeller and von Winterfeldt26 label as ‘myo-
pic problem representation’. In addition, risk attitude and other biases
were exhibited by 80 European medical assessors answering online
questionnaires about hypothetical investigational drugs treating cen-
tral nervous system, cardiovascular and oncology disorders.27 These
biases can be minimized by applying group elicitation techniques for
quantifying the subjective components.26
In multi-criteria decision analysis (MCDA), “algorithms” simply
aggregate the components to give an overall benefit–safety balance,
i.e. ‘handing back’ the inputs in changed form, which often stimulates
new insights about the benefit–safety balance. Furthermore, as the
model is explored to see why the overall result was obtained, the pro-
cess helps participants to construct their value preferences. All this is
more easily accomplished with numbers than with words alone, and it
provides the group with sufficient clarity for an informed decision to
be taken. The model only aggregates; it does not replace human
judgement, nor does it dictate the ‘right’ solution.
MCDA is a methodology for weighing options on individual, often
conflicting criteria, and combining them into one overall appraisal, tak-
ing into account both the value of outcomes and their uncertainty, as
well as all the items in Figure 2. Howard Raiffa, the founder of deci-
sion analysis, described the spirit of the process as “divide and con-
quer: decompose a complex problem into simpler problems, get one's
thinking straight on these simpler problems, paste these analyses
together with logical glue, and come out with a program of action for
the complex problem.”28 The logical glue is the algorithm for combin-
ing the components of the model.
In the 1960s and 1970s, decision analysis texts and applications
focused on problems involving uncertainty,29 but extensions to deci-
sion theory broadened the discipline to include decisions with multi-
ple, often conflicting, objectives.30 MCDA now encompasses both
uncertainty and value. Using MCDA to model the benefit–risk bal-
ance of drugs would include representing uncertainties as probabili-
ties and values defined as numerical measures of the extent to
which outcomes realize their associated objectives. The algorithm
for combining these two is to multiply value by probability, just as
you would judge the fair value of a 50–50 chance of winning
$1,000 to be $500.
Since algorithms usually outperform unaided human judgement,
and explicit quantification can reduce bias among assessors, in the
next section, we will describe how such algorithms can be employed
in regulatory decision-making.
4 | EUROPEAN EXPERIENCE WITH
QUANTITATIVE BENEFIT–RISK MODELLING
AND THE PROACT-URL FRAMEWORK
Two extensive reviews, conducted under the auspices of the EMA
(as part of the Benefit–Risk Methodology Project and the IMI-
PROTECT project), examined the suitability of a variety of fully quan-
titative models for regulatory decision-making.7,31 The EMA's CHMP
has explored the use of MCDA for modelling drug benefit–risk bal-
ance. The PROTECT project concluded that “All teams chose MCDA
… because of its comprehensiveness, accommodation of any effect
metrics and value judgements, and support for trade-off weighting, all
requirements for a fully quantitative model.”7Although numerous
MCDA approaches and methods exist, they share most of their key
steps.32 Perhaps the most generic framework is PrOACT-URL,33
which was adapted for benefit–risk assessment as part of EMA's Ben-
efit Risk Project.21 This framework, outlined in Table 1, acted as the
progenitor of a series of qualitative frameworks that emerged for the
evaluation of drug benefit–risk balance,34–36 including FDA's own
BRF recommendations.4
Benefit–risk MCDA models do not need to be very complex. The
concept of requisite decision modelling can be adopted, defined as
the model for which the form and content are sufficient to solve a
particular problem.37 This can be achieved through a ‘socio-technical
decision analysis’ approach, in which the technical decision-analytic
modelling and the group discussion are in a reflexive relationship, each
supporting the other, leading to a shared understanding among partic-
ipants of the issues that inform the final decision.38 For example, a
preliminary complex model can be trimmed down by eliminating
effects that negligibly affect the overall benefit–risk balance, identi-
fied by sensitivity analyses that explore imprecision of the data and
differences in judgements. Ideally, an impartial facilitator guides the
process as part of face-to-face workshops39 or decision confer-
ences.40 Current best practices for MCDA in health care, including the
appropriate identification and selection of criteria, are extensively dis-
cussed elsewhere.41,42
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This facilitated-group process has been applied by several phar-
maceutical manufacturers to compare their products with other drugs
for the same medical condition. Recent examples include Reckitt
Benckiser for over-the-counter analgesics,43 Merck Serono for multi-
ple sclerosis44 and Pfizer for post-operative analgesics and overactive
bladder.46 In every case, the company explored the literature to
establish three to five favourable effects and up to 11 or
12 unfavourable effects, gathered the associated data, and created a
model in a decision conference of company and external experts and
clinicians, facilitated by one of the co-authors. The independent exter-
nal experts assessed trade-off values, made changes and provided an
impartial validation of the model and its results. In every case, the
overall results revealed features about the differences among the
drugs that had not been evident from the individual data, which
would enable prescribers to better target a drug for an individual
patient. For example, in the overactive bladder case, the benefit–risk
balances of two drugs were shown in the MCDA to be worse than
the placebo. The high safety score for the placebo plus its small bene-
fit exceeded the sums of the small-to-modest benefits and poor
safety of the drugs.
Among the main benefits of MCDA in the evaluation of new
medicines is its comprehensiveness in terms of enabling simultaneous
incorporation of several dimensions of value of the favourable effects
and loss of value by the unfavourable effects. Additionally, it is possi-
ble to test the effects of stakeholders' views about clinical relevance,
including patients.46 Importantly, benefits include the ability to facili-
tate the constructive thinking of decision-makers about their own
preferences47 and value trade-offs between different evaluation
criteria, therefore improving transparency and consistency of deci-
sion outcomes.
A number of misinterpretations could be raised that are per-
ceived to act as challenges for MCDA applications in benefit–risk
assessment, relating to limitations of clinical trial evidence. For
example, the lack of a randomized control arm in a drug's pivotal
clinical study would not be something for MCDA to solve. Clearly,
any analysis involving some type of modelling is as good as the input
data used to populate the model, however various MCDA features
could be used to mitigate the impact of such limitations. For exam-
ple, sensitivity analyses of confidence interval limits could be suffi-
cient to address variability among individual patient-level effects,
whereas probabilistic sensitivity analysis could be used to identify
potential safety issues to be included in risk mitigation programs.
Past experience in the field indicates that experts participating in
MCDA studies are often happy to handle evidence limitation and
data quality issues by assigning less weight to criteria for which data
are considered to be poor.41
Interestingly enough, MCDA and decision conferencing had been
acknowledged by the US National Academies of Science, Engineering
and Medicine's Committee on Ethical and Scientific Issues in Studying
the Safety of Approved Drugs since 2012 as the only methodology
that could lead to a consistent decision-making framework across the
lifecycle of new drugs, while also allowing for input from patients and
other stakeholders (Appendix, Recommendation 2.1).48
5 | EMA CASE STUDY: BELIMUMAB FOR
SYSTEMIC LUPUS ERYTHEMATOSUS
The following section illustrates an application of the PrOACT-URL
process in developing a fully quantitative decision-analytic model with
EMA regulators and clinical experts. More precisely, this case study
focuses on belimumab (Benlysta), when it was first reviewed for
approval by the EMA for the indication of systemic lupus
erythematosus (SLE). We believe this is the first case to report how a
fully quantitative model helped to resolve differences of judgements
among drug regulators. It has been disguised but faithfully reports the
process and results as reported in publicly available documents.49,50
Interested readers could seek further information on MCDA for
medicinal products and health care decisions elsewhere.38,41
1 | Problem
Early in 2011, EMA regulators preparing the 150-day report were
finding it difficult to agree about whether belimumab (Benlysta), the
first new drug in 56 years for treating SLE, should be approved. All
agreed the drug's benefits were modest but disagreed about some
safety issues.
TABLE 1 The PrOACT-URL framework for drug benefit–risk
assessment
Problem Determine the nature of the problem and its
context.
Frame the problem.
Objective Establish objectives that indicate the overall
purposes to be achieved.
Identify criteria for (a) favourable effects, and (b)
unfavourable effects.
Alternatives Identify the options to be evaluated against the
criteria.
Consequences Describe how the alternatives perform for each of
the criteria, i.e., the magnitudes of all effects,
their desirability or severity, and the incidence of
all effects.
Trade-offs Assess and report the balance between favourable
and unfavourable effects.
Uncertainty Report the uncertainty associated with the
favourable and unfavourable effects.
Consider how the balance between favourable and
unfavourable effects is affected by uncertainty.
Risk tolerance Judge the relative importance of the
decision-maker's risk attitude for this product.




Consider the consistency of this decision with
similar past decisions and assess whether taking
this decision could impact future decisions.
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2 | Objective
A one-day decision conference was convened to determine if a deci-
sion analysis model of the benefit–risk balance of belimumab could
help to resolve the disagreements among regulators sufficiently for
them to agree a recommendation to the CHMP. Two clinical asses-
sors, one non-clinical assessor, a quality assessor and a pharmacist, all
of whom were familiar with the data about belimumab, served as
experts in the decision conference, which was facilitated by one of
the co-authors and assisted by an EMA assessor who provided com-
puter modelling support.
3 | Alternatives
1. Belimumab 10 mg
2. Belimumab 1 mg
3. Placebo
4 | Consequences
The group agreed the six favourable and three unfavourable effects,
i.e. evaluation criteria, shown in the drug's Effects Table (Table 2);
the effects' operational definitions, their measurement units and the
performance of the alternative treatment options are also shown.
For the selection of the effects, the decision conference facilitator
asked questions to ensure the effects were preference independent,
even in cases of a common cause. To provide a common metric for
all effects, all data were converted to 0–100 preference value scales,
with zero assigned to the least well-performing drug and 100 to the
best-performing drug on each scale. Conversions were either direct
linear transformations (larger numbers are more preferred) or indirect
linear (smaller numbers are more preferred, as for all unfavourable
effects). An exception to the linear transformation was Flare rate, for
which a non-linear value function was deemed more appropriate
over the whole range from 0 to 5 cases per patient year, as shown in
Figure3. The value function shows that the loss of value from no
flares is 10 points for one flare, 30 for two, 40 for three and levelling
off thereafter.
TABLE 2 Effects, definition, units and performance used in the MCDA case study with EMA regulators on the use of belimumab for systemic
lupus erythematosus
Effect Definitions Units Weight 10 mg 1 mg PBO
Favourable effects
SLEDAI 4–6% improved Percentage of patients with at least 4 points
reduction in SLEDAI at week 52
% 2.3 16 15 18
SLEDAI > 6% improved Percentage of patients with more than 6 points
reduction in SLEDAI at week 52
% 5.9 37 33 23
PGA % no worse Percentage of patients with no worsening in
Physician's Global Assessment
% 1.2 75 76 66
BILAG A/B Percentage of patients with no new BILAG A/B % 3.5 75.2 70.1 69.0
CS sparing Percentage of patients that reduced the dose of
corticosteroids (CS) by more than 25% and to less
than 7.5 mg/day
% 3.9 15.5 20.0 12.3
Flare rate Number of new BILAG A cases per patient-year Number 39.1 2.88 2.90 3.51
Unfavourable effects
Potential serious adverse events
(SAEs)
Potential for developing tumour, adverse interactions
with vaccines and AE on pregnancies
Direct
judgement
16.0 0 90 100
Infections Proportion of patients with serious infections that
are life-threatening
% 23.4 5.2 6.8 5.2
Sensitivity reaction Proportion of patients with hypersensitivity reactions % 4.7 0.4 1.3 0.1
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; PGA: Physician's Global Assessment; BILAG: British Isles Lupus Assessment Group. All
scales are defined in Mosca, M., Bombardieri, S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumat. 2006;24(Suppl. 43):S100-S104.
F IGURE 3 Value function of the flare rate criterion
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5 | Trade-offs
The purpose of weighting in decision theory is to ensure that the units
of preference value on the different scales are equivalent, thus
enabling weighted scores to be compared and combined across the
criteria. Weights are scale factors that represent the extent of trade-
offs between criteria, as 9 Fahrenheit units equate to 5 Celsius units
of temperature.
To assess criteria weights, the process of swing-weighting was
used. Two steps in thinking must be separated. First, it is necessary to
consider the objective difference in effect size between the least and
most preferred effects on a given criterion; that is available from the
evidence. The next step is to think about how much that difference
matters; this is essentially a judgement of the clinical relevance of the
difference in effect size. “How big is the difference and how much do
you care about that difference?” This is the question that was posed in
comparing the 0-to-100 swing in effect on one scale with the 0-to-100
swing on another scale, usually comparing only two effects at a time.
During the assessment process, the facilitator applied various
techniques to minimize bias in making these necessarily subjective
judgements. For example, ratios of weights are compared: the weight
on the primary endpoint, SLEDAI, is the sum of the weights on its two
criteria, 8.2, and that was judged to be about twice as much added
benefit as for CS sparing at 3.9. Flare rate's weight of 39.1 is a little
more than twice SAE's 16. Participants usually revised their original
assessments after these checks. The final weights are shown in the
Effects Table (Table 2). Note that a weight is not the importance of
the criterion; instead, it represents the added clinical value from least
preferred to most preferred in the context of the other criteria.
With preference values established and weights agreed, the com-
puter simply multiplies the values by the weights (after dividing them
by 100) and those weighted values are summed, representing a linear
additive model. The resulting weighted preference values are inter-
preted as benefits for the favourable effects and safety for the
unfavourable effects.
Figure 4 shows overall weighted preference value scores, with
favourable effects, i.e. benefits, as green and unfavourable effects,
i.e. safety, as red (so that more red means safer). The 1 mg drug
shows an overall positive balance, with too little benefit associated
with the placebo and too little safety for the 10 mg dose. Clinical
judgement captured in the model favoured the 1 mg dose as a rea-
sonable compromise between the stronger dose and the placebo.
However, the overall benefit–safety balance scores are very close to
each other, reflecting the difficulty experts were experiencing in
agreeing about belimumab. Figure 5 shows the contribution of each
criterion to the overall scores. It is clear that the largest contributors
to safety are potential SAEs and infections, with some differences in
sensitivity reactions.
6 | Uncertainty
Weights are necessarily subjective judgements and participants felt
uncertain about the numbers they had agreed. A sensitivity analysis
shows how increasing or decreasing the weight on an effect results in
a change in the overall benefit–safety balance. Sensitivity analyses on
all the unfavourable effects left assessors with a dilemma: a slight
increase in the weight on sensitivity reaction, as shown in Figure 6,
favours the placebo, or a slight decrease in weight for potential SAEs,
as shown in Figure 7, favours the 10 mg dose. Clinical judgement cap-
tured in this model favoured the 1 mg dose as a reasonable compro-
mise between the stronger dose and the placebo, and that might have
resolved the experts' disagreements.
However, no SAEs were actually observed in the clinical trials. By
setting the weight on potential SAEs to zero, the model showed over-
all preference values of 46, 33 and 33 for Benylsta 10 mg, 1 mg and
placebo, respectively, a clear win for the 10 mg dose. The model hel-
ped to resolve disagreements among the regulators and experts, and
three months later, the CHMP gave a positive opinion about
belimumab (though they had not been shown the model). More pre-
cisely, some regulators had argued for the 10 mg dose based on its
superior benefits over the 1 mg dose, whereas others felt that the
potential for SAEs in the 10 mg dose could lead to an unsafe approval.
By removing SAEs from consideration, the 10 mg dose showed a
F IGURE 4 Overall weighted preference value scores of treatment
options, illustrating benefits (green) vs. safety (red)
F IGURE 5 Overall weighted preference value scores of treatment
options, illustrating individual criteria contributions (different colours)
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6-point lead over the 1 mg dose, and regulators agreed that the level
of benefit sufficiently outweighed the risk, especially as no SAEs had
been observed in the clinical studies. This is a good example of how
numbers can deepen understanding of disagreements that are not
easily resolvable with words.
7 | Risk tolerance
The analysis revealed the importance of possible serious adverse
events and how these could substantially affect the benefit–safety
balance. The European Public Assessment Report emphasized the
importance of a long-term follow-up study.
8 | Linked decision
There is no link to past decisions, but in future this analysis could
serve as a starting point for modelling new drugs about lupus, as for
belimumab the decisions about what effects to consider were based
solely on existing drugs to treat the medical condition (which is why
the potential for SAEs was included) as well as the clinical findings.
One issue raised in the decision conference was the double cou-
nting of patients in the two SLEDAI scores, which were originally
defined as ‘At least a 4-point reduction’ and ‘More than 6-points
reduction’. The percentage of patients satisfying the latter also sat-
isfies the former, so some patients were counted twice, exaggerating
the impact of the reduction. Here the definitions that appear in the
above Effects Table result in a simple frequency distribution, and the
weight on SLEDAI 4–6% was reduced to accommodate the range of
smaller percentage reductions.
6 | MCDA FOR REGULATORY BENEFIT–
RISK RECOMMENDATIONS
The main feature of MCDA is that it provides a way for transforming
the objective measure of a drug's performance into a common metric
of preference value across all its effects versus one or more compar-
ators. This is accomplished by establishing plausible ranges of the
effects data and making informed judgements about the clinical rele-
vance of those ranges. With all effects transformed to a common
metric of preference value, and weights assigned about the clinical
relevance of the ranges of data, it becomes possible to add benefits
to safety, thus providing an overall index number of added clinical
value for a drug.
This explicit process and its results improve the “clarity and
consistency in communicating the reasoning behind drug regulatory
decisions” that are the objectives of the BRF in the following
ways: (i) listing the favourable and unfavourable effects makes clear
which benefits and risk criteria were considered by the regulator,
(ii) the list of effects provides guidance to pharmaceutical compa-
nies of what matters (and, perhaps more importantly, what does
not matter) to the regulators, and it ensures consistency for the
regulator in dealing with new drugs for the same medical condi-
tion, (iii) weights make explicit the extent of risk attitudes by the
assessors, which helps to reduce bias in the model, and (iv) MCDA
uses an algorithm for combining the pieces making up the benefit–
safety balance, which overcomes the inherent bias of focusing on
a single or small number of effects.
F IGURE 6 Sensitivity analysis on the weight of the sensitivity
reaction criterion.
The vertical red line is located at the current weight for that effect
(4.7) and it intersects the sloping lines at their current overall
preference values (38 for 10 mg, 42 for 1 mg, 40 for PBO)
F IGURE 7 Sensitivity analysis on the weight of the potential
SAEs criterion.
The vertical red line is located at the current weight for that effect
(16.0) and it intersects the sloping lines at their current overall
preference values (38 for 10 mg, 42 for 1 mg, 40 for PBO)
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The European experience with EMA on the use of quantitative
decision analysis following the Benefit–Risk Methodology Project
and the IMI-PROTECT projects has demonstrated the prospects of
using these methods for assessing drug benefit–risk balance and facil-
itating regulatory decisions. Today, although the EMA does not con-
duct or place a requirement for quantitative decision analytic
methods, it accepts the submission of such evidence and conducts
the review of relevant studies. More tangibly though, the EMA
encourages the use of quantitative frameworks via the full implemen-
tation of the Effects Table, which forms a fundamental task in data
collection, synthesis and analysis of evidence as part of quantitative
decision analysis methods.
Beyond that, it would be challenging to identify the impact that
any such studies might have had so far on informing regulatory deci-
sions: EMA regulators do not report in the European Public Assess-
ment Reports (EPARs) how they come to make their decisions; CHMP
meetings are not transcribed and are not open to the public; and EMA
guidance documents explain what must be taken into account and
reported, but not how the information will be put together. The dis-
closure of value judgements and value preferences seems to be a very
sensitive issue.
Further elaboration of the FDA's BRF elements could benefit
from the eight-step PrOACT-URL process following the European
experience, either by adopting it in full, in part or just by using a simi-
lar approach. For example, in terms of partial adoption, incorporating
an ET into public documents after a new drug is evaluated would
improve the transparency and communicability of the regulatory deci-
sion, as it has for the EMA. Indeed, the discipline of constructing the
table has proved to clarify the thinking of the regulators. In the case
of full adoption, regulatory communication could be further improved
by the systematic disclosure of the model used, such as the value tree
of favourable and unfavourable effects that supported the decision.
Whilst judgements and opinions may vary over time and geographical
regions, this would create a major opportunity for a transparent dia-
logue and appraisal of clinical relevance.
Besides assessing drug benefit–risk balance for regulatory
approval, quantitative decision analysis could also be used for other
regulatory decisions such as the appropriate timing of a vaccine's
approval for a pandemic. An example would be a quantitative model-
ling application on the risk–benefit impact of H1N1 influenza vac-
cines, to inform the decision between approval based on limited data
or waiting for more data to become available.51 The findings
suggested that quantitative models might be helpful to regulators for
such public health issues characterized by considerable uncertainty,
thus making them directly relevant to the current Covid-19 pan-
demic situation.
If a quantitative model is to be constructed, who should do it? An
interesting parallel is provided by what the FDA and EMA require for
a new product's submission: statistical data related to the primary
endpoint and, possibly, of secondary endpoints. Each organization's
statisticians are available to comment on experimental design and sta-
tistical methods used to analyse the data. Perhaps the same capability
should exist for MCDA modelling, with each applicant supplying its
MCDA model and the regulator critiquing the submitted MCDA
model if not constructing its own model from the submitted data. In
either case, the regulator could then explore differences of opinion,
value judgements, and trade-off assessments by conducting sensitivity
analyses. Ultimately, agencies will need to become competent at
interpreting MCDA models for their validity, as they have learned to
identify good statistical practice.
7 | CONCLUSION
While the FDA has recently started to implement a qualitative deci-
sion framework, the EMA has been testing quantitative frameworks
for about a decade and now will take note of any quantitative model
of the benefit–risk balance in regulatory submissions of applications
for marketing authorization of medicinal products. If the FDA decides
to move towards a more quantitative framework based on the deci-
sion sciences literature and the past European experience of benefit–
risk methodologies in drug regulatory decision-making, it is apparent
that structured decision analysis approaches such as MCDA could
accommodate all necessary features of a solid and robust benefit–
risk assessment. Other ongoing FDA initiatives relating to incorpora-
tion of patient preferences, the MIDD Pilot Program, and RWE,
would act as further opportunities for the use of a quantitative
framework as it could consolidate their outputs and enhance drug
regulatory decision-making.
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